首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.
【24h】

Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.

机译:鼠肝纤维化的巨噬细胞疗法募集宿主效应细胞,改善纤维化,再生和功能。

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the mechanisms of benefit remain undefined. Cells of the monocyte-macrophage lineage have key roles in the development and resolution of liver fibrosis. Therefore, we tested the therapeutic effects of these cells on murine liver fibrosis. Advanced liver fibrosis was induced in female mice by chronic administration of carbon tetrachloride. Unmanipulated, syngeneic macrophages, their specific BM precursors, or unfractionated BM cells were delivered during liver injury. Mediators of inflammation, fibrosis, and regeneration were measured. Donor cells were tracked by sex-mismatch and green fluorescent protein expression. BM-derived macrophage (BMM) delivery resulted in early chemokine up-regulation with hepatic recruitment of endogenous macrophages and neutrophils. These cells delivered matrix metalloproteinases-13 and -9, respectively, into the hepatic scar. The effector cell infiltrate was accompanied by increased levels of the antiinflammatory cytokine interleukin 10. A reduction in hepatic myofibroblasts was followed by reduced fibrosis detected 4 weeks after macrophage infusion. Serum albumin levels were elevated at this time. Up- regulation of the liver progenitor cell mitogen tumor necrosis factor-like weak inducer of apoptosis (TWEAK) preceded expansion of the progenitor cell compartment. Increased expression of colony stimulating factor-1, insulin-like growth factor-1, and vascular endothelial growth factor also followed BMM delivery. In contrast to the effects of differentiated macrophages, liver fibrosis was not significantly altered by the application of macrophage precursors and was exacerbated by whole BM. CONCLUSION: Macrophage cell therapy improves clinically relevant parameters in experimental chronic liver injury. Paracrine signaling to endogenous cells amplifies the effect. The benefits from this single, defined cell type suggest clinical potential.
机译:骨髓(BM)细胞疗法治疗肝硬化的临床研究正在进行中,但获益机制仍不确定。单核细胞-巨噬细胞谱系的细胞在肝纤维化的发展和消退中起关键作用。因此,我们测试了这些细胞对鼠肝纤维化的治疗作用。通过长期施用四氯化碳在雌性小鼠中诱发晚期肝纤维化。未操纵的同源巨噬细胞,其特定的BM前体或未分离的BM细胞在肝损伤期间被递送。测量炎症,纤维化和再生的介质。通过性别不匹配和绿色荧光蛋白表达追踪供体细胞。 BM衍生的巨噬细胞(BMM)递送导致早期趋化因子上调,并通过肝脏募集内源性巨噬细胞和中性粒细胞。这些细胞分别将基质金属蛋白酶13和-9传递到肝瘢痕中。效应细胞浸润伴随着抗炎细胞因子白介素10水平的升高。在输注巨噬细胞4周后,肝成纤维细胞减少,纤维化减少。此时血清白蛋白水平升高。肝祖细胞有丝分裂原肿瘤坏死因子样凋亡的弱诱导物(TWEAK)的上调在祖细胞区室扩张之前发生。 BMM递送后,集落刺激因子-1,胰岛素样生长因子-1和血管内皮生长因子的表达也增加。与分化的巨噬细胞的作用相反,巨噬细胞前体的应用并未明显改变肝纤维化,而整个BM加剧了肝纤维化。结论:巨噬细胞治疗改善了实验性慢性肝损伤的临床相关参数。旁分泌信号传导至内源性细胞可增强这种作用。这种单一,确定的细胞类型的益处表明了其临床潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号